A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease

NCT00317369 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

29

Enrollment

INDUSTRY

Sponsor class

Stopped Efficacy was not cleared at US study

Conditions

Crohn Disease

Interventions

DRUG: OPC-6535(Tetomilast)

Sponsor

Otsuka Pharmaceutical Co., Ltd.